Literature DB >> 19824880

Activated dormant Cryptococcus gattii infection in a Dutch tourist who visited Vancouver Island (Canada): a molecular epidemiological approach.

Ferry Hagen1, Sander van Assen, Gert Jan Luijckx, Teun Boekhout, Greetje A Kampinga.   

Abstract

An ongoing outbreak of Cryptococcus gattii-caused infections, which emerged on Vancouver Island and the Pacific Northwest, has affected more than 200 of the islands' residents, of whom eight died. While C. gattii infections are rarely described in travelers, we report a case of cryptococcosis caused by C. gattii in a patient treated with high dose corticosteroids for systemic lupus erythematosus induced autoimmune hemolytic anemia. She acquired the disease during a visit to Vancouver Island one year before the onset of the symptoms. This indicates that C. gattii may cause a dormant infection that can be activated during treatment with corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19824880     DOI: 10.3109/13693780903300319

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  24 in total

1.  The search for the natural habitat of Cryptococcus gattii.

Authors:  Ferry Hagen; Teun Boekhout
Journal:  Mycopathologia       Date:  2010-04-23       Impact factor: 2.574

2.  Cryptococcus neoformans/Cryptococcus gattii species complex in southern Italy: an overview on the environmental diffusion of serotypes, genotypes and mating-types.

Authors:  Orazio Romeo; Fabio Scordino; Valeria Chillemi; Giuseppe Criseo
Journal:  Mycopathologia       Date:  2012-04-25       Impact factor: 2.574

3.  Cryptococcal meningitis in patients with autoimmune hemolytic anemia.

Authors:  YaLi Yang; Junjun Sang; Weihua Pan; Lin Du; Wanqing Liao; Jianghan Chen; Yuanjie Zhu
Journal:  Mycopathologia       Date:  2014-06-21       Impact factor: 2.574

Review 4.  Cryptococcus gattii: a resurgent fungal pathogen.

Authors:  Vishnu Chaturvedi; Sudha Chaturvedi
Journal:  Trends Microbiol       Date:  2011-08-29       Impact factor: 17.079

5.  Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.

Authors:  Ferry Hagen; María-Teresa Illnait-Zaragozí; Jacques F Meis; William H M Chew; Ilse Curfs-Breuker; Johan W Mouton; Andy I M Hoepelman; Lodewijk Spanjaard; Paul E Verweij; Greetje A Kampinga; Ed J Kuijper; Teun Boekhout; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

6.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

7.  Cryptococcus gattii infection in an immunocompetent patient from Southern Italy.

Authors:  Roberta Iatta; Ferry Hagen; Cecilia Fico; Nunzia Lopatriello; Teun Boekhout; Maria Teresa Montagna
Journal:  Mycopathologia       Date:  2011-11-05       Impact factor: 2.574

8.  Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors:  P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-01       Impact factor: 3.267

9.  Fatal Cryptococcus gattii genotype AFLP5 infection in an immunocompetent Cuban patient.

Authors:  María T Illnait-Zaragozí; Lilia M Ortega-Gonzalez; Ferry Hagen; Gerardo F Martínez-Machin; Jacques F Meis
Journal:  Med Mycol Case Rep       Date:  2013-02-09

10.  Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States.

Authors:  Edmond J Byrnes; Wenjun Li; Yonathan Lewit; Hansong Ma; Kerstin Voelz; Ping Ren; Dee A Carter; Vishnu Chaturvedi; Robert J Bildfell; Robin C May; Joseph Heitman
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.